Clinical Trial: Conversion Therapy with Irinotecan Liposome (II) plus Oxaliplatin, 5-FU/S-1, Adebrelimab, and Recaticimab in Borderline Resectable or Locally Advanced Pancreatic Cancer: A Single-Arm Exploratory Study (China)

China, Aug. 24 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Conversion Therapy with Irinotecan Liposome (II) plus Oxaliplatin, 5-FU/S-1, Adebrelimab, and Recaticimab in Borderline Resectable or Locally Advanced Pancreatic Cancer: A Single-Arm Exploratory Study'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600130597

Registration Time: 2026/08/21

Type: Interventional study

Primary Sponsor: Chinese PLA General Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=338299

Published by HT Digital Content Services with permission from Health Daily Digest....